Cisplatin induced cell killing and chromosomal aberrations in CHO cells: treated during G 1 or S phase
Mutation Research/DNA Repair, ISSN: 0921-8777, Vol: 293, Issue: 2, Page: 161-172
1993
- 27Citations
- 6Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations27
- Citation Indexes26
- 26
- CrossRef17
- Clinical Citations1
- PubMed Guidelines1
- Captures6
- Readers6
Article Description
Variation in sensitivity to cisplatin during the cell cycle was studied synchronous cells treated during G 1 or late S phase. The cells were assayed for cell killing, cell-cycle delay, and chromosomal aberrations after they were treated with cisplatin (1–12 μg/ml) for 1 h at 37°C. They were either plated for colony survival, or colcemid was added from 12 to 40 h after plating followed by fixation 4 h later for analysis of chromosal aberrations after the cells completed 1 or 2 cycles (i.e. first or second mitosis). Cells treated with 6 μg/ml exhibited about a 10-h delay during the first cycle after treatment during G 1 compared with about 3 h during the first cycle and 6 h during the second cycle after treatment during late S. In both cases, cells entering metaphase exhibited predominantly chromatid-type breaks and exchanges. For both cell killing and chromosomal aberrations, the cells in G 1 were 1.5–1.6 times more sensitive than those treated in late S, with 1 aberration per cell corresponding to about 37% survival. However, the exchanges and breaks were observed primarily in the first mitosis when cells were treated in G 1 compared with the second mitosis when cells were treated in late S. These results suggest that DNA replication opposite cisplatin cross-links in the DNA results in lethal chromosomal aberrations.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/092187779390067Q; http://dx.doi.org/10.1016/0921-8777(93)90067-q; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0027507187&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/7678144; http://linkinghub.elsevier.com/retrieve/pii/092187779390067Q; http://api.elsevier.com/content/article/PII:092187779390067Q?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:092187779390067Q?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/092187779390067Q; http://dx.doi.org/10.1016/0921-8777%2893%2990067-q; https://dx.doi.org/10.1016/0921-8777%2893%2990067-q
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know